Celcuity Trial Finds 21.5-Month Progression-Free Survival in Breast Cancer Subgroup

Patients with PIK3CA-mutated disease and no liver metastases had median progression-free survival of 21.5 months on the gedatolisib triplet, versus 9.1 months on the control regimen.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.